Antje Zeise - Epigenomics AG Insider

Manager Investor Relations

We currently do not have informatin regarding Antje Zeise. This executive tanure with Epigenomics AG is not currenlty determined.
49 30 243 450

Management Efficiency

The company has return on total asset (ROA) of (25.16) % which means that it has lost $25.16 on every $100 spent on asset. This is way below average.

Similar Executives

Entity Summary

Epigenomics AG, a molecular diagnostics company, engages in developing and commercializing a pipeline of proprietary solutions for screening and diagnosis of cancer in Europe, North America, and internationally. Epigenomics AG [EPGNF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Did you try this?

Run Idea Breakdown Now

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaixs investment ideas are predefined, sector-focused investing themes
Hide  View All  Next  Launch Idea Breakdown
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Epigenomics AG to your portfolio

Top Management

Epigenomics AG Leadership Team
Albert Weber, President
Antje Zeise, Executive
Guenther Reiter, Executive
Gregory Hamilton, CEO, MBA
Ann Kessler, Executive
Heino Prondzynski, Chairman
Thomas Taapken, CFO
Annett Dietrich, Executive
Noel Doheny, CEO
Nicola HennebergBusse, President
Uwe Staub, President, Ph.D
Peter Vogt, Executive

Stock Performance

Epigenomics AG Performance Indicators